How Can CPNs Revolutionize Medical Diagnostics?
In this interview conducted at MEDICA 2022, our CEO, Andy Chaloner, spoke with NewsMedical about how our Conjugated Polymer Nanoparticles could revolutionise applications in diagnostics.
In this interview conducted at MEDICA 2022, our CEO, Andy Chaloner, spoke with NewsMedical about how our Conjugated Polymer Nanoparticles could revolutionise applications in diagnostics.
In this article in The Medicine Maker, our CEO, Andy Chaloner, discusses the shift in business priorities and resulting opportunities during the COVID-19 pandemic with Stephane Argivier, CEO of MIP Diagnostics.
This infographic in The Pathologist outlines timelines for our collaborative project with MIP Diagnostics Ltd to create a highly sensitive diagnostic reagent for SARS-CoV-2.
This technical article on Sigma Aldrich outlines the structural and optical properties of our CPNs in detail and reviews the many sectors our Conjugated Polymer Nanoparticles have already enhanced.
This article in Chemistry World gives an overview of the history of magnetism, its uses in everyday life and exciting applications that span multiple key scientific industries.
This article from Physics World explores the new wave of ‘biosensors’ for detecting microorganisms and how our revolutionary CPNs could improve such detection techniques.
In this article, our CEO, Andy Chaloner, and Commercial Director, Steve Self, discuss how Stream Bio got to where it is today.
Our Commercial Director, Steve Self, talks to Physics World about what Brexit means for Stream Bio and how he is determined to make the best of the situation.
This article explores the advantages of our revolutionary CPNs over existing in vitro cell-imaging agents and molecular probes.
In this article, find out how electronic technology inspired our unique CPNs and how they could revolutionise the future of bioimaging.